BD holds true to legacy of improving patient outcomes

Even after 120 years since founding BD in New Jersey, Maxwell Becton and Fairleigh Dickinson’s genuine concern for patients lives on. With more than 50,000 associates in more than 50 countries today, the global medical technology company has developed perhaps the world’s most efficient and reliable medical devices for drug administration, diagnostics and life sciences research.

“We have collectively put our energies behind the company’s core purpose and value of doing what is right and treating people with respect,” says James Lim, executive vice-president and president for Greater Asia. “We continuously strive to meet societal needs by elevating health care, best practices and public awareness while developing the most efficient ways of treating people for better outcomes.”

This philosophy runs at the core of all BD’s undertakings from as simple as developing better drug administration and management methods through to combating serious diseases. The group, for instance, has pioneered the use of pre-filled medications such as flu vaccines and insulin shots to promote safety, efficacy and cost savings as each pre-filled medication contains only the exact dosage. BD is also automating the identification of infectious diseases and their corresponding treatments while developing technologies that can accurately monitor human immunity levels as an alternative treatment for cancer.

Eager to share these technologies with other countries, BD wishes to broaden its global network of partners as it explores frontier markets such as Myanmar, Cambodia, Laos, Bangladesh and Sri Lanka.

“We want to be known in these countries as a partner that has truly improved their health care systems and one that has helped them attain the outcomes they aspire to,” Lim says. “We are open for business and welcome companies with a similar corporate vision to join us as we enhance our licensing, acquisition and partnership activities throughout the region.”